Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia
- 4 May 2004
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 72 (6) , 441-443
- https://doi.org/10.1111/j.1600-0609.2004.00257.x
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJNCI Journal of the National Cancer Institute, 1998